Literature DB >> 18358277

End-of-life decision before and after birth: changing ethical considerations.

Andrew B Pinter1.   

Abstract

Despite the dramatic improvement in the outcome of somatically handicapped neonates, vexing ethical issues remain. In which fetuses would termination be indicated? In which neonates are the malformations so serious that surgery and intensive care should not be initiated (withholding or not starting treatment)? Conversely, in which neonates should the initiated treatment be stopped (withdrawal of treatment)? These questions pose huge medical, legal, ethical, moral, and financial problems for doctors, lawyers, ethicists, and families. Fetuses and neonates with congenital anomalies can be divided into 6 groups: 1, those who have the potential for total recovery; 2, those with anomalies that would allow for a nearly normal life; 3, those with malformations requiring permanent supervision and/or medical care; 4, those with somatic rest defect and subnormal mental development; 5, those with serious somatic and mental damage; and 6, those with anomalies that are incompatible with life. The decision making should be tailored to each of these groups. The pediatric surgeon, besides taking into consideration the quantity and quality of the rescued life, should lower the anxiety of the parents, should follow the morals of a civilized society, should act according to the law, and finally, should convince himself to be a solution to a problem and not to be a cause of any.

Entities:  

Mesh:

Year:  2008        PMID: 18358277     DOI: 10.1016/j.jpedsurg.2007.09.054

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

1.  Involuntary euthanasia of severely ill newborns: is the Groningen Protocol really dangerous?

Authors:  P Voultsos; F Chatzinikolaou
Journal:  Hippokratia       Date:  2014 Jul-Sep       Impact factor: 0.471

2.  Major chromosomal anomalies among very low birth weight infants in the Vermont Oxford Network.

Authors:  Nansi S Boghossian; Jeffrey D Horbar; Joseph H Carpenter; Jeffrey C Murray; Edward F Bell
Journal:  J Pediatr       Date:  2011-12-16       Impact factor: 4.406

3.  Ethical problems in pediatrics: what does the setting of care and education show us?

Authors:  Jucélia Maria Guedert; Suely Grosseman
Journal:  BMC Med Ethics       Date:  2012-03-16       Impact factor: 2.652

4.  Physicians' attitudes in relation to end-of-life decisions in Neonatal Intensive Care Units: a national multicenter survey.

Authors:  Ilias Chatziioannidis; Zoi Iliodromiti; Theodora Boutsikou; Abraham Pouliakis; Evangelia Giougi; Rozeta Sokou; Takis Vidalis; Theodoros Xanthos; Cuttini Marina; Nicoletta Iacovidou
Journal:  BMC Med Ethics       Date:  2020-11-23       Impact factor: 2.652

5.  Consultation of parents and healthcare professionals in end-of-life decision-making for neonates and infants: a population-level mortality follow-back physician survey.

Authors:  Kim Beernaert; Kenneth Chambaere; Laure Dombrecht; Filip Cools; Joachim Cohen; Luc Deliens; Linde Goossens; Gunnar Naulaers
Journal:  BMC Pediatr       Date:  2022-10-14       Impact factor: 2.567

6.  How old are you? Newborn gestational age discriminates neonatal resuscitation practices in the Italian debate.

Authors:  Emanuela Turillazzi; Vittorio Fineschi
Journal:  BMC Med Ethics       Date:  2009-11-12       Impact factor: 2.652

7.  Decision-making at the limit of viability: differing perceptions and opinions between neonatal physicians and nurses.

Authors:  Hans Ulrich Bucher; Sabine D Klein; Manya J Hendriks; Ruth Baumann-Hölzle; Thomas M Berger; Jürg C Streuli; Jean-Claude Fauchère
Journal:  BMC Pediatr       Date:  2018-02-22       Impact factor: 2.125

8.  A post-mortem population survey on foetal-infantile end-of-life decisions: a research protocol.

Authors:  Laure Dombrecht; Kim Beernaert; Ellen Roets; Kenneth Chambaere; Filip Cools; Linde Goossens; Gunnar Naulaers; Luc De Catte; Joachim Cohen; Luc Deliens
Journal:  BMC Pediatr       Date:  2018-08-03       Impact factor: 2.125

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.